Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auditory safety study of Coartem in uncomplicated Plasmodium falciparum malaria
2016-004321-16Phase 4
- Sponsor
- Novartis
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of artemether + lumefantrine, atovaquone + proguanil and artesunate + mefloquine in Malaria (3 arms), sponsored by Novartis. Primary endpoint: Rate of ABR Wave III latency changes of > 0.3 msec.
02
Drugs
artemether + lumefantrineatovaquone + proguanilartesunate + mefloquine
03
Conditions
Malaria
Beyond the preview
Go deeper on 2016-004321-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004321-16.